Russia's strategic-medicine procurement rules change on 1 December, making evidence of manufacturing inside the Eurasian Economic Union central to preferential treatment. The changes distinguish medicines made entirely within the bloc from products lacking verified production records, with transitional dates for some additions to the strategic list. They concern purchasing rules, rather than a general prohibition on imported medicines.1
For the first section of the strategic list, ConsultantPlus explains that manufacturers must support their claim with a Russian or Eurasian industrial-register entry showing at least 100 localisation points. The Industry and Trade Ministry must also publish information about a verified batch of the offered medicine, or another medicine with the same international non-proprietary name. Manufacturing stages are checked through the Chestny Znak tracking system.1
Winning a preference creates delivery obligations
The government decree makes the geographical scope explicit:
все стадии производства
all manufacturing stages.2
The requirement includes synthesis of the active-substance molecule. Under the specified preference arrangements, the purchasing contract must require delivery from a batch whose regional manufacturing stages have been confirmed through the monitoring system. At acceptance, the supplier must provide information confirming that the ministry has published the relevant batch details.2
The decree also prevents substitution of an agreed fully regional product with one that does not meet that manufacturing condition. This makes production traceability a condition of contract performance, extending the significance of origin beyond the initial tender. A factory address alone does not establish that the delivered batch satisfies the stipulated manufacturing chain.2
Registrations and factories measure different things
The documentary transition was already visible during the summer. In its 31 August analysis, trade publication Pharmvestnik counted 224 medicines in the Russian industrial-products register. It described the shift from origin certificates towards register entries and documents identifying manufacturing stages. That dated count is a snapshot of administrative coverage, rather than a count of every domestically manufactured medicine or evidence of national output growth.3
Investment announcements show how producers are preparing for state demand. On 4 November, Ozon Pharmaceuticals said two Togliatti factories would begin commercial production in 2027. Ozon Medica is intended for chemotherapy medicines and Mabscale for biotechnology products. The company said their output would primarily serve government procurement.4
Ozon reported that Medica received its manufacturing licence in August and that Mabscale registered its first biotechnology medicine in late October. Medica's initial tablet and capsule section is designed for up to 4.6 million packs annually. These are separately identifiable milestones: a licence, a product registration and a statement of capacity. They do not mean that the projected annual volume has already been produced or delivered.4
The commercial test is therefore the conversion of manufacturing investment into documented, eligible batches and fulfilled orders. The new procurement conditions reward a verified production chain, while the company's timetable places the additional commercial factory output in the following year.24